Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.59 |
| ▸ | CCR3 | P51677 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.49 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.49 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.49 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6570399 | 0.92 | GBA1 (0.52) | GBA1CCR3ACHECARM1PRMT6 | |
| SCHEMBL2027845 | 0.89 | GBA1 (0.71) | GBA1CCR3CARM1PRMT6PRMT3 | |
| SCHEMBL674276 | 0.89 | GBA1 (0.71) | GBA1CCR3CARM1PRMT6PRMT3 | |
| SCHEMBL4609517 | 0.88 | GBA1 (0.50) | GBA1CCR3ACHE | |
| Ammonia Solution, Strong SCHEMBL1432566 | 0.86 | GBA1 (0.68) | GBA1CCR3CARM1PRMT6PRMT3 | |
| Hydrochloric Acid SCHEMBL4797146 | 0.84 | GBA1 (0.65) | GBA1CCR3CARM1PRMT6PRMT3 | |
| SCHEMBL8101593 | 0.83 | GBA1 (0.82) | GBA1CCR3ACHECARM1PRMT6 | |
| SCHEMBL8101596 | 0.83 | CCR3 (0.59) | CCR3ACHECARM1PRMT6PRMT3 | |
| SCHEMBL16191226 | 0.83 | GBA1 (0.59) | GBA1CCR3CARM1PRMT6PRMT3 | |
| SCHEMBL16191130 | 0.82 | GBA1 (0.53) | GBA1CCR3CARM1PRMT6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1017 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025214693-A1 | CATALYST MATERIAL AND USE THEREOF FOR DEHYDROGENATING HYDROGEN CARRIER MATERIALS | HYDROGENIOUS LOHC TECHNOLOGIES GMBH (DE) | 2025-10-16 | — | — | WO | claimed |
| US-4818748-A | HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-04-04 | — | — | US | claimed |
| EP-0236874-A2 | Renin inhibitors, their production and use, as well as derivatives of amino acids and amino aldehydes | BAYER AG (DE) | 1987-09-16 | — | — | EP | claimed |
| US-20260138121-A1 | SUPPORTED NICKEL-COPPER CATALYST FOR DEHYDROGENATION AND HYDROGENATION OF LIQUID ORGANIC HYDROGEN CARRIERS | CHEVRON U S A INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2025214693-A1 | CATALYST MATERIAL AND USE THEREOF FOR DEHYDROGENATING HYDROGEN CARRIER MATERIALS | HYDROGENIOUS LOHC TECHNOLOGIES GMBH (DE) | 2025-10-16 | — | — | WO | disclosed |
| EP-4601788-A1 | CATALYST SYSTEM AND METHOD FOR CATALYTICALLY DEHYDRATING A HYDROGEN CARRIER MATERIAL, REACTOR ARRANGEMENT WITH SUCH A CATALYST SYSTEM AND METHOD FOR PRODUCING SUCH A CATALYST SYSTEM | HYDROGENIOUS LOHC TECHNOLOGIES GMBH (DE) | 2025-08-20 | — | — | EP | disclosed |
| US-12269018-B2 | Platinum-sulfur-based shell catalyst, production and use thereof in the dehydrogenation of hydrocarbons | CLARIANT INTERNATIONAL LTD (CH) | 2025-04-08 | — | — | US | disclosed |
| WO-2025042907-A1 | SULFIDATED NOBLE METAL ON METAL DOPED SUPPORT AS A HYDROGENATION AND DEHYDROGENATION CATALYST | CHEVRON U.S.A. INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20250065311-A1 | SULFIDATED NOBLE METAL ON METAL DOPED SUPPORT AS A HYDROGENATION AND DEHYDROGENATION CATALYST | CHEVRON USA INC (US) | 2025-02-27 | — | — | US | disclosed |
| US-12043573-B2 | Adhesion promoters and gel-modifiers for olefin metathesis compositions | MATERIA, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-3386936-B1 | OLEFIN METATHESIS CATALYSTS | UMICORE AG & CO KG (DE) | 2024-07-10 | — | — | EP | disclosed |
| US-6518243-B1 | Desleucyl glycopeptide antibiotics and methods of making same | TRUSTEES OF PRINCETON UNIVERSITY | 2003-02-11 | — | — | US | disclosed |
| EP-1173193-A4 | DESLEUCYL GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF MAKING SAME | UNIV PRINCETON (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020042365-A1 | Vancomycin analogs | TRUSTEES OF PRINCETON UNIVERSITY, THE | 2002-04-11 | — | — | US | disclosed |
| EP-1173193-A1 | DESLEUCYL GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF MAKING SAME | The Trustees of Princeton University (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000059528-A1 | DESLEUCYL GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF MAKING SAME | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1016670-A1 | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5977062-A | ACTIVE AGAINST ANTIBIOTIC RESISTANT BACTERIA | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| US-4818748-A | HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-04-04 | — | — | US | disclosed |
| EP-0236874-A2 | Renin inhibitors, their production and use, as well as derivatives of amino acids and amino aldehydes | BAYER AG (DE) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138121-A1 | SUPPORTED NICKEL-COPPER CATALYST FOR DEHYDROGENATION AND HYDROGENATION OF LIQUID ORGANIC HYDROGEN CARRIERS | NUDC, SOD1, TIMM10 | GBA1 4512/4885CCR3 1308/4885ACHE 3707/4885 |
| US-20020042365-A1 | Vancomycin analogs | VNN1, PTMS, ASNS | GBA1 2232/4885CCR3 151/4885ACHE 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.